UNIT

Radiopharmacy

"The incorporation of the new PET-CT, together with the use of radiopharmaceuticals, allows us to detect lesions that until now were practically impossible to identify".

DR. IVÁN PEÑUELAS SÁNCHEZ
DIRECTOR. RADIOPHARMACY UNIT

The Clinic's Radiopharmacy Unit is the only Spanish hospital with the capacity to synthesize and apply 20 different radiopharmaceuticals.

The benefit for our patients of this wide variety of radiopharmaceuticals is that it allows a more precise diagnosis to determine the most appropriate treatment for complex pathologies such as prostate, brain and liver tumors, degenerative diseases such as Parkinson's or Alzheimer's and dementias in general.

The radiopharmaceutical is used as a contrast compound that is injected into the patient to observe the interior of the body in vivo, in a non-invasive way. The objective is to obtain the molecular image of the organism itself or of the specific disease to be studied.

Our facilities for the elaboration of radiopharmaceuticals comply with GMP (Good Manufacturing Practices) conditions or internationally established standards of correct elaboration.

Therefore, we apply the maximum safety conditions in the production of the medicines, both in radiological protection and in the personalized dosage for each patient.

Imagen del icono de la consulta de Segunda Opinión. Clínica Universidad de Navarra

Do you need us to help you?

Contact us

PET Service and Radiopharmacy Unit join forces to obtain maximum diagnostic and therapeutic accuracy

The Clinic is one of the European hospitals that has a greater number of specific radiopharmaceuticals for certain pathologies for clinical use in the center itself and about a fortnight in research and clinical trials

IN NAVARRE

The PET (Positron Emission Tomography) technique allows a very advanced and precise early image diagnosis in different pathologies, especially of tumors.

The singularity is that the metabolic changes that are detected by this technique, thanks to the activity of the radiopharmaceutical, are previous to the structural ones so it is possible to detect the alterations at a molecular level, before their anatomical perception.

Hence the possibility of a very early diagnosis of the disease that will result in a better prognosis. In addition, this technique also provides early information on the patient's response to treatment, by observing the modifications.

<p>Imagen del equipo PET-TAC</p>

Technified radiopharmaceuticals

  • 99mTc- Phytacis®
    Technetium Phytate
    Use: liver scan
  • 99mTc- Nanocis®
    Rhenium Colloidal Sulfide
    Utilization: lymphographies and gastroesophageal scintigraphy
  • 99mTc- MAG-3®
    Benzoyl mercapto acetyl triglycine
    Utilization: evaluation of nephrological and urological disorders
  • 99mTc- Bridatec®
    Mebrofenin
    Utilization: hepatobiliary imaging and hepatobiliary function studies
  • 99mTc-DMSA
    Technetium Succuminum
    Use: static renal imaging
  • 99mTc-PYP
    Sodium pyrophosphate anhydrous
    Utilization: red blood cell marking, blood volume determination and spleen scan
  • 99mTc-HDP
    Oxydrate
    Use: bone scan
  • 99mTc-MAA (Lyomaa®)
    Albumin macro-aggregates
    Utilization: lung perfusion scan and venography scan
  • 99mTc-Cardiolite®
    Sestamibi
    Use: diagnosis of decreased coronary perfusion, myocardial infarction, diagnosis of breast cancer malignancy and in hyperparathyroidism
  • 99mTc- Myoview®
    Tetrofosmin
    Utilization: cardiac and breast scan
  • 99mTc- Ceretec®
    HMPAO (examethylene p-amino oxime, exametazim)
    Use: brain scan and leukocyte marking with 99mTc
  • 99mTc-DTPA
    Technetium Pentetate
    Utilization: renal scan, cerebral angiogammagraphy, cerebral scan, pulmonary ventilation scan and gastroesophageal reflux and gastric emptying studies
  • 99mTc- Ceretec® stabilized
    HMPAO (examethylene p-amino oxime, exametazim)
    Utilization: brain scaN
  • 99mTc- Vasculocis®
    HSA (human serum albumin)
    Bone marrow imaging, areas of abdominal swelling, and lymphatic system integrity study
  • 99mTc- Nanocoll®
    Colloidal human albumin
    Utilization: vascular phase imaging, angiocardiography and ventriculography

Non-technical radiopharmaceuticals

  • 90Y- ZEVALIN®
    Ibritumomab tuxetan
    Utilization: treatment of adult patients with non-Hodgkin's lymphoma
  • 111In- Octeoscran®
    PenteotridUtilization: diagnosis of carcinoid and gastro-entero-hepatic neuroendocrine tumors

Do you need to request a consultation with one of our specialists?

DIAGNOSIS AND PERSONALIZED TREATMENT

Pioneers in technology

The Clinic has become the pioneering Spanish center in the field of Radiopharmacy, especially in its use with the PET technique.


Radiopharmaceuticals

Approximately 95% of radiopharmaceuticals are used for diagnostic purposes and therefore their application does not have a therapeutic purpose like regular drugs. Each radiopharmaceutical has a recommended dose range for each of the authorised clinical indications.


Quality and Safety

Radiopharmaceuticals are the safest medicines available because, in addition to the rigorous controls to which they are subjected, the doses administered to patients are so low that there is no possibility of adverse effects.


Unique facilities

GMP installations comply with a unidirectional flow of materials and products. The laboratory guarantees radiological protection, both for the personnel working in the radioactive facility and for the rest of the Clinic's professionals and the public in general.

Imagen de la fachada de consultas de la sede en Pamplona de la Clínica Universidad de Navarra

Why choose Navarra?

  • Precise diagnosis thanks to the combination of PET and radiopharmaceutical.
  • National references professionals in this type of technique.
  • We research together with the rest of the Clinic's departments in order to offer therapeutic alternatives to our patients.

Good Manufacturing Practices, internationally established standards of good manufacturing

Highest quality
Nuclear Medicine GMP Laboratory

The implementation of this PET GMP laboratory, in 2009, obtained the approval of the Department of Innovation, Business and Employment of the Government of Navarra, with the favourable report of the Nuclear Safety Council (CSN).

The laboratory is subject to inspections by the Government of Navarra's Department of Health and the CSN.

We help our patients to overcome their stories

Their testimonies encourage us to continue improving our services

Safer than ever to continue taking care of you

We update safety protocols weekly with the latest scientific evidence and the knowledge of the best international centers with which we collaborate.